

MEETING ABSTRACT

Open Access

PW02-022 - Recurrent fever syndromes: multiple gene mutations

M Bohm^{1*}, P Dolezalova¹, H Lachmann², C Modesto³, I Touitou⁴, P Woo⁵, M Finetti⁶, V Hentgen⁷, L Cantarini⁸, F De Benedetti⁹, R Gallizzi¹⁰, L Obici¹¹, R Manna¹², E Gallo¹³, N Ruperto⁶, M Gattorno⁶, EUROFEVER/PRINTO network

From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID) Lausanne, Switerland. 22-26 May 2013

Introduction

In patients with monogenic autoinflammatory diseases, the majority of detected mutations were found just in a single gene, either in homozygous, heterozygous or compound heterozygous state. However, in some patients mutations in several different genes have been detected. Clinical significance of this finding has yet to be established.

Objectives

To describe clinical characteristics of patients with rare combinations of genetic mutations.

Methods

Seventy-seven centres from 33 countries have been contributing to an international secured web-based registry for autoinflammatory diseases (EUROFEVER), hosted by the PRINTO website (Paediatric Rheumatology International Trial Organisation, http://www.printo.it).

The registry collects anonymised demographic, clinical, laboratory and molecular genetic data on patients with autoinflammatory diseases. Complete clinical information on 1868 consecutive children was available.

Results

In 31 patients (1.7%), the combination of mutations in two different genes, and in one patient in three genes was found with following distribution of clinical diagnoses: Cryopyrin-Associated Periodic Syndromes (CAPS)=9, Tumor necrosis factor (TNF)-Receptor Associated Periodic Syndrome (TRAPS)=7, Familial Mediterranean Fever (FMF)=5, mild Mevalonate Kinase Deficiency

(MKD, also known as Hyper IgD Syndrome (HIDS))=2, undefined=9. Out of these patients 18 (56%) carried one high penetrance mutation each. The prevalence of high penetrance mutations among clinically defined groups was most prominent within the CAPS phenotype (8/9) followed by FMF (3/5), MKD (1/2) and TRAPS (3/7). In patients with low penetrance mutations in one of the 4 relevant genes the second mutation was found in one of the remaining 3 genes with the following characteristics: low penetrance (5/14), polymorphisms (3/14), unknown (4/14). In remaining 2 patients the combination of unknown penetrance mutation in one gene and polymorphism in the other was found (both with undefined phenotype).

Conclusion

As the availability of molecular genetic analysis for patients with recurrent fever syndromes increases, the amount of detected mutations in more than one gene will grow. The data currently available suggest that the high prevalence mutations overrule the clinical picture of the disease in majority of patients, though clinical significance of second mutations will have to be evaluated in larger patient series.

Disclosure of interest

None declared.

Authors' details

¹Charles University in Prague, Prague, Czech Republic. ²University College Medical School, London, UK. ³Hospital Valle de Hebron, Barcelona, Spain. ⁴Hôpital Arnaud de Villeneuve, Montpellier, France. ⁵Great Ormond Street Hospital, London, UK. ⁶Istituto Giannina Gaslini, Genova, Italy. ⁷Centre de reference national des maladies auto-inflammatoires, Paris, France.

¹Charles University in Prague, Prague, Czech Republic Full list of author information is available at the end of the article



⁸University of Siena, Siena, Italy. ⁹Ospedale Pediatrico Bambin Gesù, Roma, Italy. ¹⁰Università di Messina, Messina, Italy. ¹¹Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy. ¹²Policlinico Gemelli, Roma, Italy. ¹³Clinica Pediatrica Università di Torino, Torino, Italy.

Published: 8 November 2013

doi:10.1186/1546-0096-11-S1-A162

Cite this article as: Bohm *et al.*: PW02-022 - Recurrent fever syndromes: multiple gene mutations. *Pediatric Rheumatology* 2013 11(Suppl 1):A162.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

